Fresenius Medical Care AG & Co. KGaA (FMS)

NYSE: FMS · IEX Real-Time Price · USD
20.06
+0.62 (3.19%)
At close: Mar 21, 2023, 4:00 PM
19.70
-0.36 (-1.79%)
After-hours: Mar 21, 2023, 7:31 PM EDT
3.19%
Market Cap 11.77B
Revenue (ttm) 19.40B
Net Income (ttm) 673.41M
Shares Out 586.83M
EPS (ttm) 1.15
PE Ratio 16.31
Forward PE 9.92
Dividend $1.43 (7.13%)
Ex-Dividend Date May 13, 2022
Volume 1,239,979
Open 19.93
Previous Close 19.44
Day's Range 19.81 - 20.10
52-Week Range 12.79 - 34.65
Beta 0.88
Analysts Sell
Price Target 18.88 (-5.88%)
Earnings Date May 3, 2023

About FMS

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage rena... [Read more]

Sector Healthcare
IPO Date Sep 19, 1996
Employees 122,758
Stock Exchange NYSE
Ticker Symbol FMS
Full Company Profile

Financial Performance

In 2022, FMS's revenue was $19.40 billion, an increase of 10.10% compared to the previous year's $17.62 billion. Earnings were $673.41 million, a decrease of -30.53%.

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for FMS stock is "Sell." The 12-month stock price forecast is $18.88, which is a decrease of -5.88% from the latest price.

Price Target
$18.88
(-5.88% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Fresenius Medical's (FMS) Q4 Earnings and Revenues Beat

Fresenius Medical's (FMS) fourth-quarter revenues benefit from strong performance across all segments, especially in the North America and Asia-Pacific regions. However, rising costs hurt margins.

3 weeks ago - Zacks Investment Research

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

Dear Investor:

Other symbols: ETOGNTAROTEVAVTRS
3 weeks ago - GuruFocus

Fresenius Medical Care takes action to close global health gaps, signs "Zero Health Gaps" Pledge at the World Economic Forum

WALTHAM, Mass. , Jan. 20, 2023 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has taken the Zero Health Gaps P...

2 months ago - PRNewsWire

Bear of the Day: Fresenius Medical (FMS)

Profit estimates are moving in the wrong direction.

4 months ago - Zacks Investment Research

Fresenius Medical's (FMS) Q3 Earnings and Revenues Top

Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

4 months ago - Zacks Investment Research

Fresenius Medical cuts outlook on slower recovery, rising costs

Kidney dialysis provider Fresenius Medical Care (FMC) on Sunday revised down its forecast for 2022, expecting net income to decline this year, dragged down by rising labour costs and a slower than exp...

5 months ago - Reuters

Investor Elliott has taken stake in Germany's Fresenius -Bloomberg

Elliott Investment Management has taken a stake in Fresenius SE , seeking to potentially break up the diversified healthcare company, Bloomberg cited people familiar with the matter as saying.

5 months ago - Reuters

Fresenius Medical Care partners with National Kidney Foundation Malaysia in kidney health initiative

HONG KONG--(BUSINESS WIRE)-- #CKDprevention--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today signed a memorandum of understandi...

6 months ago - Business Wire

Fresenius Medical (FMS) Robust Product Portfolio Drives Growth

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

7 months ago - Zacks Investment Research

CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms

Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future innovations CytoSorb will b...

Other symbols: CTSO
8 months ago - PRNewsWire

Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

8 months ago - Zacks Investment Research

Fresenius now expects lower revenue, earnings in the second half, citing wage inflation and staff shortages in North America

Shares of Fresenius Medical Care tumbled 13.7% in premarket trading on Thursday after telling investors to expect lower-than-expected revenue and net income in the second half of the year. The company...

8 months ago - Market Watch

Fresenius cuts FY outlook on higher costs at dialysis business

German healthcare group Fresenius SE cut its full-year earnings outlook due to cost inflation at its kidney dialysis subsidiary Fresenius Medical Care (FMC), it said late on Wednesday.

8 months ago - Reuters

After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)

The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i...

8 months ago - Zacks Investment Research

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

8 months ago - Zacks Investment Research

Fresenius (FMS) Faces Fraud Accusation From US Government

The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures...

8 months ago - Zacks Investment Research

Highmark Interactive Inc. Announces Collaboration with Renal Research Institute to Identify Potential Biomarkers of Brain Injury in Hemodialysis Patients

The Renal Research Institute will include the Highmark digital assessment suite into its clinical research of people receiving in-center hemodialysis treatment. TORONTO, ON / ACCESSWIRE / June 20, 202...

9 months ago - Accesswire

Fresenius Medical Care Celebrates Diversity and Unity of a Global Nurse Workforce

HONG KONG--(BUSINESS WIRE)-- #healthcare--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care'...

11 months ago - Business Wire

Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.

11 months ago - Zacks Investment Research

Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care

Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.

1 year ago - Zacks Investment Research

Fresenius Medical Care Launches My Reason® Campaign to Enroll Patients in Groundbreaking Renal-focused Genomic Registry

Goal of 100,000 Participants Within Five Years to Help Scientists Better Understand Genetic Variations in Patients with Chronic Kidney Disease WALTHAM, Mass. , April 13, 2022 /PRNewswire/ -- Fresenius...

1 year ago - PRNewsWire

Fresenius Medical Care Appoints Dr. Amaka Eneanya as Head of Strategy and Operations for Company's Global Medical Office

WALTHAM, Mass. , April 5, 2022 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced today the appointment of not...

1 year ago - PRNewsWire

Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care

Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.

1 year ago - Zacks Investment Research

How Fresenius Medical Care's Superhero Is Helping Bridge the Knowledge Gap to Better Kidney Health

HONG KONG--(BUSINESS WIRE)-- #chronickidneydisease--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has today announced the social me...

1 year ago - Business Wire

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.

1 year ago - Zacks Investment Research